For decades, a brain tumour diagnosis asked patients to endure weeks of uncertainty before treatment could begin — a silence that was itself a kind of suffering. The NHS has now deployed a genomic sequencing technology that collapses that wait from eight weeks to two hours, delivering molecular clarity while surgeons are still in the operating theatre. More than 12,000 people in the UK face this diagnosis each year, and for them, speed is not merely convenience — it is the difference between weeks lost to anxiety and days gained for living. In piloting this technology across five specialist ce
NHS rapid brain tumour test cuts diagnosis time from weeks to hours
Patients with brain tumours, including those with aggressive glioblastoma, benefit from faster diagnosis enabling quicker treatment access and reduced weeks of anxiety during waiting periods.
Getting that quick diagnosis removed weeks of anxiety
Mark
So the test itself—it's not diagnosing whether someone has a brain tumour. They already know that. It's identifying which type.
Mimi
Exactly. There are about 150 different types. Some are slow-growing, some are aggressive. Treatment depends entirely on knowing which one you have. Before this, that took six to eight weeks of lab analysis. Now it takes two hours.
Luke
How confident are we in the speed claim? The source says the machine ran for 20 minutes in Steve's case, but then the team had to call the theatre. Is that 20 minutes of machine time, or 20 minutes from sample to result?
Mimi
The source says the machine was running for 20 minutes before they called. So there's some preparation time before that—the sample has to be prepared and loaded. The full process is described as two hours, which is the NHS's figure.
Mark
And the surgeons can actually change what they're doing based on the result? While the patient is still under?
Mimi
Yes. If they learn it's a slow-growing, curable type, they can be more aggressive in removing tissue. If it's aggressive and inoperable, they can be more cautious to avoid damaging healthy brain.
Luke
That's a significant claim. Do we have evidence that surgeons actually changed their approach in any of these cases, or is that theoretical?
Mimi
The source describes it as potential—what *could* happen. Smith explains the logic, but we don't have a case where the result demonstrably changed a surgical decision mid-operation.
Mark
What about the broader rollout? Is this available everywhere now?
Mimi
No, it's a pilot. Five centres to start—Nottingham, Birmingham, London, Newcastle, and Great Ormond Street. Plans to expand to eight sites total, but it's not routine care yet.
Luke
And the 12,000 people diagnosed annually—how many will actually have access during this pilot phase?
Mimi
The source doesn't say. That's a real gap. We know the scale of the need, but not how many patients the pilot will reach.
Mark
What's the actual innovation here? Is it the machine, or the software, or the process?
Mimi
The machine is Oxford Nanopore's technology. But the software was developed at the University of Nottingham in partnership with hospital clinicians. It's the combination—the hardware plus the custom analysis that makes it work in a clinical setting this fast.
Luke
And the cost? Is this expensive to run?
Mimi
Not mentioned in the source. That's another gap—we don't know the cost per test or whether it's sustainable at scale.
The Pulse
- Brain tumours encompass roughly 150 distinct types, and without genetic classification, surgeons have been making critical decisions — how aggressively to operate, how much tissue to spare — based on microscopy alone, a method one leading neuropathologist called little more than educated guesswork.
- The old diagnostic pathway forced patients to wait six to eight weeks for molecular results, delaying radiotherapy, chemotherapy, and access to clinical trials during the period when time is most precious.
- Oxford Nanopore's shoebox-sized sequencer reads tumour DNA in as little as 20 minutes, transmitting a full genetic profile to the operating theatre in real time and allowing surgeons to reshape their approach before closing the incision.
- Steve Palmer, a 55-year-old diagnosed with an aggressive grade 4 glioblastoma in Nottingham, received his genetic classification while still on the operating table — and described the speed as removing weeks of anxiety that would otherwise have preceded his fight.
- The NHS is currently piloting the technology at five specialist centres, with expansion to eight sites planned, as health leaders gather evidence to make rapid genomic testing a nationwide standard of care.
For decades, a brain tumour diagnosis asked patients to endure weeks of uncertainty before treatment could begin — a silence that was itself a kind of suffering. The NHS has now deployed a genomic sequencing technology that collapses that wait from eight weeks to two hours, delivering molecular clarity while surgeons are still in the operating theatre. More than 12,000 people in the UK face this diagnosis each year, and for them, speed is not merely convenience — it is the difference between weeks lost to anxiety and days gained for living. In piloting this technology across five specialist centres, the health service is attempting to make precision and compassion arrive at the same moment.
Steve Palmer was 55 when he collapsed at a gym in Nottingham. The tumour found inside him — a grade 4 glioblastoma, among the most aggressive brain cancers — would once have taken six to eight weeks to classify. Instead, surgeons received its genetic profile while he was still on the operating table. "Getting that quick diagnosis removed weeks of anxiety," Palmer said afterward. The result was not what he had hoped for, but the speed allowed him to move forward and begin fighting.
The technology behind this shift is a genomic sequencer made by Oxford Nanopore — a device small enough to fit in a shoebox. Tumour tissue extracted during surgery is prepared and loaded into the machine, where DNA molecules pass through microscopic holes that reveal the cancer's genetic fingerprint. In Palmer's case, the process took 20 minutes before the neuropathology team called the operating theatre with their findings.
The speed matters because brain tumours are not a single disease. Across roughly 150 distinct types, treatment strategies differ profoundly. A surgeon facing a slow-growing, potentially curable tumour must be aggressive; one confronting a rapidly fatal cancer must be cautious to protect healthy tissue. Knowing which tumour a patient has while the incision is still open can reshape the entire operation. Stuart Smith, the neurosurgeon who led Palmer's procedure, described the test as seeming "almost magical" compared to the educated guesswork that microscopy had previously required.
More than 12,000 people in the UK are diagnosed with a primary brain tumour each year, and brain cancer is the leading cancer killer of children and adults under 40. Faster diagnosis means faster access to radiotherapy, chemotherapy, and clinical trials tailored to a tumour's specific biology — trials that might never have been considered during weeks of waiting. The test does not cure brain cancer, but it removes one of its cruelest dimensions: the uncertainty that steals time before treatment can even begin.
The NHS is now piloting the technology across five specialist centres — Nottingham, Birmingham, Great Ormond Street, King's College, and Newcastle — with plans to expand to Bristol, Oxford, Leeds, and Manchester. Senior health officials have framed the ambition clearly: to gather sufficient evidence that rapid genomic testing becomes routine care, so that patients across the country benefit equally from a diagnosis that is both faster and more precise.
Steve Palmer was 55 when he collapsed at the gym in Nottingham. The diagnosis that followed—a grade 4 glioblastoma, one of the most aggressive brain tumours—would have meant weeks of waiting for answers under ordinary circumstances. Instead, surgeons operating to remove his tumour received the genetic classification of his cancer while he was still on the table. The test that made this possible takes two hours, not eight weeks. It has begun changing how the NHS diagnoses and treats brain cancer.
The technology is a genomic sequencer made by Oxford Nanopore, a shoebox-sized machine that reads the DNA fingerprint of tumour tissue. A sample extracted during surgery travels to the pathology lab, where it is prepared and loaded into the device. DNA molecules pass through a nanopore—a microscopic hole—revealing the tumour's genetic profile. In Palmer's case, the machine ran for 20 minutes before the neuropathology team called the operating theatre with their finding. What once took six to eight weeks now takes hours, sometimes minutes.
The speed matters because brain tumours are not one disease. There are roughly 150 different types, ranging from slow-growing lesions to rapidly fatal cancers, and each responds differently to treatment. A surgeon operating on a slow-growing, potentially curable tumour needs to be aggressive, removing every visible trace of cancer. A surgeon facing an aggressive, inoperable tumour must be cautious, minimizing damage to healthy brain tissue. Knowing which type of tumour a patient has while the surgeon is still in the operating theatre can reshape the entire approach to treatment. Stuart Smith, the consultant neurosurgeon who led Palmer's operation at Nottingham University Hospitals, described the test as seeming "almost magical." Before this, he relied on microscopy—educated guesswork, he acknowledged, that worked reasonably well on good days but lacked the clarity that genetic analysis provides.
Palmer, speaking to the BBC after his diagnosis, captured the human weight of the acceleration. "Getting that quick diagnosis removed weeks of anxiety," he said. He acknowledged the result was not what he hoped to hear, but the speed allowed him to move forward. "It means I can get on with the next phase of treatment and recovery, and get on with fighting whatever it is I've got to fight."
More than 12,000 people in the UK are diagnosed with a primary brain tumour each year. Brain cancer is the leading cancer killer of children and adults under 40. For these patients and their families, the weeks of waiting for a diagnosis can feel unbearable. Faster results mean faster access to radiotherapy, chemotherapy, and clinical trials—interventions that can extend life or improve its quality. For some patients, it means surgeons can make life-altering decisions about how aggressively to operate before closing the incision.
The NHS is now piloting the test across five specialist centres: Nottingham University Hospitals, University Hospitals Birmingham, Great Ormond Street Hospital in London, King's College Hospital, and Newcastle Hospitals. The pilot will later expand to Bristol, Oxford, Leeds, and Manchester. The technology builds on earlier work already underway in Nottingham and Birmingham. Prof Frankie Swords, NHS medical director, framed the rollout as transformative. A faster diagnosis, he said, means patients can start the right treatment sooner, access clinical trials sooner, and in some cases allow surgeons to make potentially life-changing decisions while still operating. Prof Dame Sue Hill, chief scientific officer for England, emphasized the ambition: to gather evidence that rapid genomic testing should become routine NHS care, so patients across the country benefit equally from faster, more precise diagnosis.
Dr Simon Paine, the consultant neuropathologist at Nottingham who interprets the results, described the shift in his own practice. Looking at tumour cells under a microscope, he said, he was "crystal ball gazing"—skilled work, but limited. The nanopore machine offers something different: a comprehensive molecular classification that leaves no room for guesswork. For patients, the benefit extends beyond speed. A full genetic profile of the tumour opens doors to clinical trials tailored to that specific cancer's biology, trials that might not have been available or even considered during weeks of waiting for a diagnosis. The test does not cure brain cancer. But it removes one of the cruelest parts of the disease: the uncertainty, the waiting, the sense that time is being stolen while answers remain locked away.
Notable Quotes
The diagnosis of brain tumours relies on molecular and genetic analysis but it can take up to six to eight weeks to get the full information back. Here it is done while we are still operating.— Stuart Smith, consultant neurosurgeon at Nottingham University Hospitals
I'm crystal ball gazing and can do it reasonably well on a good day, but nowhere near with the clarity of the nanopore, which gives a comprehensive molecular classification.— Dr Simon Paine, consultant neuropathologist at Nottingham University Hospitals
Want the full story?
Read the original at BBC News ↗